Brief: Sinomab Bioscience Says Investigational New Drug Application For Sn1011 Accepted
29/06/2020 11:34
June 29 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* SINOMAB BIOSCIENCE- INVESTIGATIONAL NEW DRUG APPLICATION
FOR
SN1011 ACCEPTED BY CENTER FOR DRUG EVALUATION OF NMPA OF CHINA
Source text for Eikon: ID:nHKS3bTDHl
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience